详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, 361003, Fujian, China. [2]Reproduction Center, The Second Affiliated Hospital of Kunming Medical University 650101, Yunnan, China.

出处：

DOI：

关键词： circulating miRNA microarray NSCLC EGFR response

摘要：

Based on recognition of driver mutations, treatment paradigm for non-small-cell lung cancer (NSCLC) patients has been shifted. However, recently exon 19 deletion mutation (del19) of epidermal growth factor receptor (EGFR) clearly shows better clinical benefit over single-point substitution mutation L858R in exon 21 (L858R). The aim of this study was to investigate the difference by analyzing the expression of plasma microRNAs (miRNAs) of NSCLC patients with EGFR mutation del19 or L858R. MiRNA microarray of plasma from patients' blood identified 79 mapped, network-eligible miRNAs (fold > 5), of which 76 were up regulated and 3 were down regulated. Genetic network was performed with Ingenuity Pathway Analysis (IPA). Among analysis, MYC, Argonaute2 (AGO2), Y-box binding protein 1 (YBX1), cyclin E1 (CCNE1) were involved in organismal abnormalities and cancer. Our findings provide information on the epigenetic signature of the two major sensitive mutations among NSCLC and add to the understanding of mechanisms underlying the different outcomes.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 1 区

医学

小类 | 2 区细胞生物学 2 区肿瘤学

最新[2023]版：

无

第一作者：

第一作者机构： [1]Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, 361003, Fujian, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study [2]Immune microenvironment could be responsible for response to immune checkpoint inhibitors among NSCLC patients with various EGFR mutation types [3]Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study. [4]Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area [5]Rh-endostatin Combined With PD-1 inhibitors as Firstline Treatment for EGFR/ALK-Negative, Nonsquamous NSCLC [6]应用基因芯片技术检测参与大肠腺瘤癌变的表皮生长因子受体信号通路的基因 [7]TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China [8]CT and MRI bimodal radiomics for predicting EGFR status in NSCLC patients with brain metastases: A multicenter study [9]Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers [10]Exploring the applicability of immunotherapy in different EGFR mutation subgroups based on data analysis of 9,659 Chinese patients with NSCLC.